ライフサイエンスコーパス: MEN

1 MEN 2B patients, running a high risk of metastatic MTC,

2 MEN activation must be reversed after mitotic exit to re

3 MEN promotes the release of the protein phosphatase Cdc1

4 MEN was consumed for a mean of 10.8 months (range 4-14 m

5 MENs and control ferromagnetic and polymer nanoparticles

6 MENs distinguish cancer cells from normal cells through

7 es with multiple endocrine neoplasia type 1 (MEN 1), with the ultimate aim of early tumor detection a

8 osis of multiple endocrine neoplasia-type 1 (MEN-1).

9 Multiple endocrine neoplasia type 2 (MEN 2) is an inherited cancer syndrome that includes phe

10 Multiple endocrine neoplasia type 2 (MEN 2) syndrome is an autosomal dominant, hereditary can

11 sion of multiple endocrine neoplasia type 2 (MEN 2), a dominantly inherited cancer predisposition.

12 (VHL), multiple endocrine neoplasia type 2 (MEN 2), the newly delineated phaeochromocytoma-paragangl

13 types: multiple endocrine neoplasia type 2A (MEN 2A) and multiple endocrine neoplasia type 2B (MEN 2B

14 multiple endocrine neoplasia (MEN) type 2A (MEN-2A) or type 2B or familial medullary thyroid carcino

15 In multiple endocrine neoplasia 2B (MEN-2B) patients expressing RET(M918T), nuclear enrichme

16 A) and multiple endocrine neoplasia type 2B (MEN 2B) syndromes.

17 sis of multiple endocrine neoplasia type 2B (MEN 2B).

18 the 61 patients (59%) responded (MEN 2A = 8, MEN 2B = 28) to the questionnaires.

19 In this study, we show that a MEN component, protein kinase Dbf2-Mob1, promotes transf

20 Thus, only when a MEN bearing SPB leaves the mother cell and the spindle i

21 zone model', exit from mitosis occurs when a MEN-bearing SPB enters the bud.

22 We aimed to assess how achievable MEN is and whether it helps to prolong remission.

23 An additional MEN-activating function of Lte1 is mediated by its N- an

24 We find that hypertonic stress allows MEN mutants to exit from mitosis in a manner dependent o

25 MEN kinases with both SPBs serves to amplify MEN signaling, enabling the timely exit from mitosis.

26 ciated lung adenocarcinoma transcript 1) and MEN beta, are formed by cleavage by RNase P and are capp

27 Comparisons of MEN 2B and MEN 2A MTCs revealed that genes involved in the process

28 ter consisting mainly of primary adenoma and MEN 1 tumors.

29 iated with both intestinal aganglionosis and MEN-associated tumors.

30 se from Cfi1/Net1 during early anaphase, and MEN maintains Cdc14 in the released state during late an

31 We propose that these CPC- and MEN-dependent mechanisms are important for coordinating

32 explain co-existing Hirschsprung disease and MEN-associated tumors, but rather that RET overstimulati

33 nd late anaphase, controlled by the FEAR and MEN pathways, respectively.

34 ast, FEAR (Cdc14 early anaphase release) and MEN (mitotic exit network) activate phosphatase Cdc14 by

35 1 negatively regulate the homologous SIN and MEN pathways.

36 ated phosphorylation of the Cbk1 HM site and MEN-activated reversal of mitotic CDK phosphorylations t

37 50% solid component), functional tumors, and MEN-1 patients were excluded.

38 An NKII antagonist (MEN 10,376, 500 nM) had no effect on the evoked response

39 suggesting compensatory interactions between MEN, IDH, and G6PD.

40 e to electric-field interactions (i) between MENs and a drug and (ii) between drug-loaded MENs and ce

41 d two bacterial datasets, and show that both MEN and BBSR infer accurate GRNs even when the structure

42 ely positioned along the mother-bud axis can MEN signaling occur and cell division proceed.

43 ction distinct from that known for classical MEN 2B mutations.

44 We showed that the constructed MENs under both warming and unwarming conditions exhibit

45 A sub group of patients can continue MEN as a maintenance treatment and this seems a useful s

46 15/48 (31%) patients were able to continue MEN post EEN completion.

47 nts who took EEN were encouraged to continue MEN post EEN.

48 ssion rates at 1 year in patients continuing MEN were 60% (9/15) compared to 15% (2/13) in patients t

49 However, p27(-/-) mice develop MEN-like tumors only in combination with loss of another

50 properties of cells which result in distinct MEN organization and the minimization of electrical ener

51 dSPB and that association of the downstream MEN kinases with both SPBs serves to amplify MEN signali

52 14/15 patients drank MEN and 1/15 had MEN via NGT.

53 ughter cell asymmetry determinants establish MEN signaling asymmetry through microtubule-bud cortex i

54 lasmic microtubules collaborate to establish MEN asymmetry.

55 To examine MEN proteins during mitotic exit, we imaged the MEN acti

56 There are two competing models that explain MEN regulation by spindle position.

57 represent a possible therapeutic avenue for MEN-associated neoplasms.

58 spindle pole bodies (SPBs) is necessary for MEN signaling during mitosis, during meiosis MEN signali

59 ermline mutations in RET are responsible for MEN 2 but the precise pathogenetic mechanisms of tumorig

60 c thyroidectomy and diagnostic screening for MEN-associated endocrine diseases should occur.

61 se findings reveal kinetochores as sites for MEN signaling and implicate MEN in coordinating chromoso

62 ce for somatic VHL gene deletion in all four MEN 2A-related pheochromocytomas.

63 Forty-four MEN 2B patients carrying inherited (3 patients) and de n

64 ized activating signal is necessary for full MEN activation.

65 14/15 patients drank MEN and 1/15 had MEN via NGT.

66 associated with tumorigenesis in hereditary, MEN 2-related pheochromocytoma.

67 2A, eight patients with HD were identified (MEN 2A-HD).

68 res as sites for MEN signaling and implicate MEN in coordinating chromosome segregation and/or spindl

69 th the presence of skeletal abnormalities in MEN 2B patients.

70 noted in 8% of cases and were more common in MEN-1 patients.

71 , cutaneous lesions classically described in MEN 2B syndrome, and 1 relative also showing multiple sc

72 may explain the early onset of malignancy in MEN 2B compared with MEN 2A patients.

73 eletal abnormalities and early malignancy in MEN 2B compared with MEN 2A syndrome.

74 The HOG pathway drives exit from mitosis in MEN mutants by promoting the activation of the MEN effec

75 thoracic neuroendocrine tumors that occur in MEN 1 carry a malignant potential.

76 y nuclear localized Cdc14, the key player in MEN pathway, indicative of MEN activation.

77 th factor beta pathway, were up-regulated in MEN 2B MTCs.

78 tex has an important but ill-defined role in MEN regulation.

79 was expressed at high levels specifically in MEN 2B MTCs.

80 but also of p18 expression is a key step in MEN tumorigenesis.

81 hibition by DRB treatment, was suppressed in MEN epsilon/beta-depleted cells.

82 has been assumed to be the central switch in MEN regulation.

83 h is both necessary and sufficient to induce MEN signaling.

84 lls, where it is ideally situated to inhibit MEN signaling at spindle pole bodies (SPBs) when anaphas

85 (SPBs) located in the mother cell to inhibit MEN signaling.

86 his domain within Cdc15 functions to inhibit MEN signaling.

87 MENs and a drug and (ii) between drug-loaded MENs and cells.

88 void its premature release, (ii) drug-loaded MENs could be delivered into cancer cells via applicatio

89 Only the mice treated with PTX-loaded MENs (15/200 mug) in a field for three months were compl

90 The bud-localized MEN regulator Lte1, whose molecular function has long be

91 patterns of MEN and SPoC components mediate MEN inhibition.

92 MEN signaling during mitosis, during meiosis MEN signaling occurs off SPBs and does not require the S

93 sely, our data show that benign meningiomas (MENs), which contain less water than brain tissue, are c

94 However, in metazoans, MEN and Cdc14 function is not conserved.

95 Furthermore, unlike during mitosis, MEN signaling is controlled through the regulated intera

96 To ensure the accurate execution of mitosis, MEN activity is coordinated with other cellular events a

97 hways distinct from those involved in mutant MEN 1-related parathyroid tumors.

98 Among 41 patients with de novo mutations, MEN 2B was diagnosed in 12 patients after recognition of

99 We used magnetoelectric nanoparticles (MENs) to control drug delivery and release.

100 Magnetoelectric (ME) nanoparticles (MENs) intrinsically couple magnetic and electric fields.

101 The multiple endocrine neoplasia (MEN) syndromes present a diverse array of challenges to

102 ET can lead to multiple endocrine neoplasia (MEN) syndromes.

103 scent of human multiple endocrine neoplasia (MEN) syndromes.

104 Multiple endocrine neoplasia (MEN) type 1 and type 2 exhibit an autosomal dominant pat

105 patients with multiple endocrine neoplasia (MEN) type 2A (MEN-2A) or type 2B or familial medullary t

106 patients with multiple endocrine neoplasia (MEN) type 2A or 2B, related syndromes that result from d

107 Multiple endocrine neoplasia (MEN) types 1 and 2 are rare hereditary cancer syndromes

108 ssociated with multiple endocrine neoplasia (MEN) types 2A and 2B and familial MTC (FMTC) have mutati

109 tomas (15 with multiple endocrine neoplasia [MEN] 2A, 4 with MEN 2B, 1 each with von Hippel-Lindau an

110 Both methods [Modified Elastic Net (MEN) and Bayesian Best Subset Regression (BBSR)] extend

111 anaphase, whereas the mitotic exit network (MEN) activates Cdc14 during late stages of anaphase.

112 bf4 also regulates the mitotic exit network (MEN) and monopolar homolog orientation in meiosis I.

113 ng pathways termed the mitotic exit network (MEN) and the septation initiation network (SIN) keeps Cd

114 Release of the mitotic exit network (MEN) component, Cdc14p, from the nucleolus during anapha

115 parase (Esp1); and the mitotic exit network (MEN) driven by interaction between the spindle pole body

116 ion pathway called the mitotic exit network (MEN) governs the transition from mitosis to the G1 phase

117 d axis to activate the mitotic exit network (MEN) in anaphase.

118 The mitotic exit network (MEN) in S. cerevisiae and its homologous network, the se

119 ccharomyces cerevisiae mitotic exit network (MEN) is a conserved signaling network that coordinates C

120 ccharomyces cerevisiae mitotic exit network (MEN) is a conserved signaling network that coordinates e

121 The budding yeast mitotic exit network (MEN) is a GTPase-driven signal transduction cascade that

122 The budding yeast mitotic exit network (MEN) is a signal transduction cascade that controls exit

123 The mitotic exit network (MEN) is an essential GTPase signaling pathway that trigg

124 anaphase release") and mitotic exit network (MEN) pathways.

125 Components in the mitotic exit network (MEN) play important roles in normal cytokinesis.

126 arly anaphase, and the Mitotic Exit Network (MEN) promotes Cdc14 release during late anaphase.

127 g cascade known as the mitotic exit network (MEN) promotes exit from mitosis.

128 In budding yeast, the Mitotic Exit Network (MEN) releases Cdc14 phosphatase from the nucleolus durin

129 tion network (SIN) and mitotic exit network (MEN) signaling pathways regulate cytokinesis and mitotic

130 g network known as the mitotic exit network (MEN) triggers exit from mitosis.

131 The Mitotic Exit Network (MEN), a budding yeast Ras-like signal transduction casca

132 clei by inhibiting the mitotic exit network (MEN), a GTPase signaling cascade that promotes exit from

133 es the activity of the mitotic exit network (MEN), a GTPase signaling pathway that promotes exit from

134 The mitotic exit network (MEN), a protein kinase cascade under the switch-like con

135 The Mitotic Exit Network (MEN), a Ras-like GTPase signaling pathway, integrates sp

136 The mitotic exit network (MEN), a Ras-like signaling cascade, promotes the release

137 orks by inhibiting the mitotic exit network (MEN), a signaling cascade initiated and controlled by Te

138 ng yeast, inhibits the mitotic exit network (MEN), a signaling pathway that promotes exit from mitosi

139 Components of the mitotic exit network (MEN), a signaling pathway that triggers exit from mitosi

140 n anaphase because the mitotic exit network (MEN), an essential Ras-like GTPase signaling cascade, is

141 cascade, known as the mitotic exit network (MEN), controls this release.

142 n budding yeast by the mitotic exit network (MEN), where Cdc14p dephosphorylates key conserved Cdk1-s

143 nase is a component of mitotic exit network (MEN), which inactivates cyclin-dependent kinase (CDK) af

144 anaphase activates the mitotic exit network (MEN), which triggers dispersal of Cdc14 throughout the c

145 elongation delays the mitotic exit network (MEN)-dependent release of Cdc14, thus delaying spindle b

146 ylate Ace2 until after mitotic exit network (MEN)-initiated release of the phosphatase Cdc14.

147 ng the activity of the mitotic exit network (MEN).

148 t is controlled by the Mitotic Exit Network (MEN).

149 x, an inhibitor of the mitotic exit network (MEN).

150 signaling cascade, the mitotic exit network (MEN).

151 osis by inhibiting the mitotic exit network (MEN).

152 exit, sitting atop the mitotic exit network (MEN).

153 timate effector of the mitotic exit network (MEN).

154 etworks named molecular ecological networks (MENs) through Random Matrix Theory (RMT)-based methods.

155 Nine MEN 1 kindreds were included in the study.

156 nts with de novo mutations when nonendocrine MEN 2B components are quickly appreciated and surgical i

157 Our studies identify a novel MEN-linked regulatory system that inhibits cytokinesis i

158 that ongoing maintenance enteral nutrition (MEN) can be beneficial in maintaining disease remission

159 hat daughter cells activate an Antagonist of MEN pathway (AMEN) in part through induction of the Amn1

160 Whereas binding of MEN components to spindle pole bodies (SPBs) is necessar

161 carriers of a RET mutation characteristic of MEN-2A had no evidence of persistent or recurrent medull

162 carriers of a RET mutation characteristic of MEN-2A underwent total thyroidectomy.

163 Comparisons of MEN 2B and MEN 2A MTCs revealed that genes involved in t

164 e position is sensed by a system composed of MEN-inhibitory and -activating zones and a sensor that m

165 ss of both is critical in the development of MEN tumors and that both p18 and p27 are regulated by RE

166 d treatment they had before the diagnosis of MEN 2.

167 mptoms 1 to 24 years before the diagnosis of MEN 2.

168 nts with de novo mutations, the diagnosis of MEN 2B was triggered by symptomatic MTC (28 patients) or

169 N 2B mutation does not cause any features of MEN 2B in mice.

170 rtained a patient with classical features of MEN 2B, but lacking either of the classical mutations in

171 24 amino acids results in hyperactivation of MEN and premature release of Cdc14 from the nucleolus, s

172 ts, we determined the relative importance of MEN signaling from the SPB that is delivered into the da

173 the key player in MEN pathway, indicative of MEN activation.

174 e Rad53 pathway alleviates the inhibition of MEN by Bfa1.

175 Knockdown of MEN epsilon/beta expression results in the disruption of

176 significantly higher than expected levels of MEN activity in knockout heterozygotes, which we attribu

177 quantitative analysis of the localization of MEN components, we determined the relative importance of

178 Cutaneous manifestations of MEN 2A syndrome include macular amyloidosis, whereas MEN

179 onent Mob1p with the SPB acts as a marker of MEN activation.

180 Our findings indicate that multiple modes of MEN regulation occur through the protein kinase Cdc15.

181 le mechanisms underlying the pathogenesis of MEN 2A-related pheochromocytoma.

182 Distinct localization patterns of MEN and SPoC components mediate MEN inhibition.

183 ar invasion (P < 0.001), and the presence of MEN-1 (P = 0.035) were prognostically significant advers

184 To identify more negative regulators of MEN, we carried out a genetic screen for genes that are

185 syndrome was included within the spectrum of MEN 2A syndrome.

186 ation of Tem1, which acts at the very top of MEN pathway.

187 The familial MTC type of MEN 2 syndrome was included within the spectrum of MEN 2

188 of 11 individuals with familial MTC type of MEN 2A syndrome demonstrated the moderate risk RET p.Val

189 ns of patients with the familial MTC type of MEN 2A syndrome.

190 e), and (iii) the drug could be released off MENs on demand via application of an a.c. field (~50 Oe,

191 s of released Cdc14 have opposite effects on MEN activation.

192 We find that BBSR outperforms MEN at inferring GRNs from expression data and noisy str

193 and activates a signal transduction pathway, MEN, to allow mitotic exit.

194 rotubule (cMT)-bud neck interactions prevent MEN activity.

195 re examined for signs and symptoms prompting MEN 2B.

196 data, the Rad53 pathway negatively regulates MEN independently of Cdc5, a Polo-like kinase essential

197 The G protein Tem1 regulates MEN activity.

198 irty-six of the 61 patients (59%) responded (MEN 2A = 8, MEN 2B = 28) to the questionnaires.

199 the MEN kinase Cdc15 to accurately restrict MEN activation to late mitosis.

200 uring an unperturbed cell cycle, restricting MEN activity to anaphase can occur in a Tem1 GTPase-inde

201 ugh Bfa1p dephosphorylation and so restricts MEN activity to a short period in anaphase.

202 may play a role in the tumorigenesis of some MEN 2A-related pheochromocytomas.

203 released by the FEAR network is to stimulate MEN activity.

204 ltiple endocrine neoplasia type 2B syndrome (MEN 2B).

205 We propose that MEN signaling is initiated by Tem1 at the dSPB and that

206 Our analysis further shows that MEN signaling is modulated during meiosis in several key

207 ME property, for the first time we show that MENs can distinguish different cancer cells among themse

208 The MEN 2 syndromes are characterized by medullary thyroid c

209 The MEN Cdc14p phosphatase is sequestered in the nucleolus a

210 The MEN GTPase Tem1 has been assumed to be the central switc

211 The MEN has been studied intensively; however, a unified und

212 The MEN inhibitory zone is located in the mother cell, the M

213 The MEN is a signaling cascade that localizes to spindle pol

214 The MEN is conserved and in metazoans is known as the Hippo

215 The MEN kinase Cdc15 first phosphorylated the scaffold Nud1.

216 ns, which, we propose, directly activate the MEN GTPase Tem1.

217 this signal and show that Lte1 activates the MEN in at least two ways.

218 hese data indicate that Cdc14p activates the MEN in early anaphase but later inactivates it through B

219 with the cortex of the bud and activates the MEN upon the formation of an anaphase spindle.

220 suggests that Cdc14p initially activates the MEN.

221 odies (SPB-centrosome equivalent) allows the MEN to couple the final stages of mitosis to spindle pos

222 e we show that the 3' ends of MALAT1 and the MEN beta long noncoding RNAs are protected from 3'-5' ex

223 ing Cdk activity is critical for ME, and the MEN contributes strongly to ME efficiency.

224 the MEN activators Tem1p and Cdc15p and the MEN regulator Bub2p in vivo.

225 a component of both the FEAR network and the MEN, in Cdc14 release from the nucleolus.

226 d Esp1 depended on spindle integrity and the MEN.

227 hrough the regulated interaction between the MEN kinase Dbf20 and its activating subunit Mob1.

228 urther show that only Cdc14 liberated by the MEN after completion of chromosome segregation, and not

229 tory zone is located in the mother cell, the MEN-activating zone in the bud, and the spindle pole bod

230 response to Tem1's activity at the dSPB, the MEN kinase cascade, which functions downstream of Tem1,

231 Only when an SPB escapes the MEN inhibitor Kin4 in the mother cell and moves into the

232 umor suppressor gene are responsible for the MEN 1 syndrome.

233 Consistent with a role for the MEN during meiosis II, we find that the signaling pathwa

234 We also found a novel role for the MEN: activating Cdc14 nuclear export, even in the absenc

235 proteins during mitotic exit, we imaged the MEN activators Tem1p and Cdc15p and the MEN regulator Bu

236 This inactivates the MEN and displaces Mob1p from SPBs.

237 ad53 prevents mitotic exit by inhibiting the MEN pathway, whereas the Chk1 pathway prevents FEAR path

238 c15p persistence at the dSPB to initiate the MEN signal cascade.

239 We show here that during meiosis, the MEN is dispensable for exit from meiosis I but contribut

240 Finally, hyperactivation of the MEN by deletion of BUB2 restores defects in cytokinesis

241 We conclude that control of the MEN by spindle position is exerted by both negative and

242 arrest in anaphase due to inhibition of the MEN by the mother cell-restricted SPoC kinase Kin4.

243 The association of the MEN component Mob1p with the SPB acts as a marker of MEN

244 ly anaphase independent of the action of the MEN components Cdc15p, Dbf2p, and Tem1p.

245 terized the functional domains of one of the MEN components, the protein kinase Cdc15, and investigat

246 N mutants by promoting the activation of the MEN effector, the protein phosphatase Cdc14.

247 uring anaphase causes the active form of the MEN GTPase Tem1 to accumulate at the dSPB.

248 that the anaphase-specific activation of the MEN in the absence of Tem1 is controlled by the Polo kin

249 Most components of the MEN localize to spindle pole bodies.

250 pole body (SPB), where the components of the MEN reside, functions as the sensor.

251 Awareness of the components of the MEN syndromes, as well as careful preoperative preparati

252 resent a compartmental, logical model of the MEN that is capable of representing spatial aspects of r

253 of BFA1 or BUB2, negative regulators of the MEN, failed to remedy the cytokinetic defect of these mu

254 the yeast Polo kinase Cdc5 converge onto the MEN kinase Cdc15 to accurately restrict MEN activation t

255 th Tem1 and Cdc5 are required to recruit the MEN kinase Cdc15 to spindle pole bodies, which is both n

256 tial signal, nuclear position, regulates the MEN GTPase Tem1.

257 Unlike Net1/Cfi1, which regulates the MEN through the Cdc14 phosphatase, Dnt1 can inhibit SIN

258 Here we describe how scaffolding the MEN onto spindle pole bodies (SPB-centrosome equivalent)

259 dc14 phosphorylation and, by stimulating the MEN, Cfi1/Net1 phosphorylation.

260 Our findings indicate that the MEN epsilon/beta non-coding RNAs are essential structura

261 Here we present evidence that the MEN protein kinase complex Mob1p-Dbf2p localizes to mito

262 We found that signaling through the MEN kinase cascade was mediated by an unusual two-step p

263 of two S. cerevisiae proteins related to the MEN proteins Mob1p and Dbf2p kinase.

264 f proteins that functions in parallel to the MEN to promote Cdc14 function.

265 at cells normally avoid this problem via the MEN-dependent release of Cdc14, which counteracts all cl

266 mother cell and moves into the bud where the MEN activator Lte1 resides can exit from mitosis occur.

267 refore central to the mechanism by which the MEN and Cdc14 initiate cytokinesis and block polarised g

268 Our results define a mechanism by which the MEN promotes exit from mitosis.

269 ssion of a human Ret proto-oncogene with the MEN 2B mutation does not cause any features of MEN 2B in

270 et cell tumors arise in association with the MEN-1 syndrome, the majority of these neoplasms are spor

271 Therefore, MEN protein localization fluctuates to switch from Bub2p

272 This MEN 2B MTC profile may explain the early onset of malign

273 drug (paclitaxel (PTX)) could be attached to MENs (30-nm CoFe2O4@BaTiO3 nanostructures) through surfa

274 asure indicates efficient Cdc14 release upon MEN activation; release driven by Esp1 in the absence of

275 Genetic testing for mutations in the VHL, MEN, and SDHB/C/D genes was performed on patients withou

276 t) facilitated response acquisition, whereas MEN-10,376 (NK2 antagonist) hindered acquisition.

277 yndrome include macular amyloidosis, whereas MEN 2B syndrome is traditionally linked to multiple muco

278 ultiple endocrine neoplasia [MEN] 2A, 4 with MEN 2B, 1 each with von Hippel-Lindau and neurofibromato

279 ny of the expected neoplasms associated with MEN 2B.

280 onset of malignancy in MEN 2B compared with MEN 2A patients.

281 and early malignancy in MEN 2B compared with MEN 2A syndrome.

282 HD 2 to 63 years before being diagnosed with MEN 2.

283 From 83 families with MEN 2A, eight patients with HD were identified (MEN 2A-H

284 asymptomatic young members of kindreds with MEN-2A who had a mutated allele of the RET proto-oncogen

285 One patient with MEN 2B underwent open adrenalectomy due to previous adre

286 ed four pheochromocytomas from patients with MEN 2A and RET germline mutations for the presence of al

287 In addition, some patients with MEN 2A develop Hirschsprung's disease (HD), and all pati

288 ns not previously described in patients with MEN 2A syndrome and to discuss the association of this d

289 ns not previously described in patients with MEN 2A syndrome.

290 All patients with MEN 2A-HD had rectal biopsies with a diverting colostomy

291 All patients with MEN 2A-HD were operated on for HD 2 to 63 years before b

292 chanisms of tumor formation in patients with MEN 2A-related pheochromocytoma.

293 These and all patients with MEN 2B followed at the authors' institution (n = 53) wer

294 Ninety-three percent of patients with MEN 2B had gastrointestinal symptoms 1 to 24 years befor

295 sprung's disease (HD), and all patients with MEN 2B have intestinal neuromas and megacolon that can c

296 Patients with MEN 2B have significant gastrointestinal symptoms, but l

297 ble to physicians have enabled patients with MEN, particularly those with the carcinoid syndrome or p

298 Seventy-one percent of patients with MEN-2B with gastrointestinal symptoms had radiographic i

299 oordinate Ace2p-dependent transcription with MEN activation.

300 R absorption spectra of cells incubated with MENs.